Search Results - "Hardingham, J."

Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research by Grover, P.K., Cummins, A.G., Price, T.J., Roberts-Thomson, I.C., Hardingham, J.E.

“…Increasing evidence suggests that circulating tumour cells (CTCs) are responsible for metastatic relapse and this has fuelled interest in their detection and…”
Get full text

The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial by Mooi, J.K., Wirapati, P., Asher, R., Lee, C.K., Savas, P., Price, T.J., Townsend, A., Hardingham, J., Buchanan, D., Williams, D., Tejpar, S., Mariadason, J.M., Tebbutt, N.C.

“…The consensus molecular subtypes (CMS) is a transcriptome-based classification of colorectal cancer (CRC) initially described in early-stage cohorts, but the…”
Get full text

Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer by Price, T J, Bruhn, M A, Lee, C K, Hardingham, J E, Townsend, A R, Mann, K P, Simes, J, Weickhardt, A, Wrin, J W, Wilson, K, Gebski, V, Van Hazel, G, Robinson, B, Cunningham, D, Tebbutt, N C

“…Background: Mutations affecting RAS genes are now established predictive markers of nonresponse to anti-EGFR antibodies in advanced CRC. This analysis assessed…”
Get full text

High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab by Kumar, S. S., Tomita, Y., Wrin, J., Bruhn, M., Swalling, A., Mohammed, M., Price, T. J., Hardingham, J. E.

“…Purpose Biomarkers, such as mutant RAS, predict resistance to anti-EGFR therapy in only a proportion of patients, and hence, other predictive biomarkers are…”
Get full text

Molecular detection of blood‐borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease by Hardingham, Jennifer E., Hewett, Peter J., Sage, Robert E., Finch, Jennie L., Nuttall, Jacqueline D., Kotasek, Dusan, Dobrovic, Alexander

“…In colorectal cancer (CRC), a proportion of patients with early stage disease still die of metastatic or recurrent disease within 5 years of “curative”…”
Get full text

Somatic mutations, acetylator status, and prognosis in colorectal cancer by Hardingham, J E, Butler, W J, Roder, D, Dobrovic, A, Dymock, R B, Sage, R E, Roberts-Thomson, I C

“…Background—Somatic mutations in K-ras and TP53 may be associated with both acetylator status and prognosis in colorectal cancer. Aims—To determine whether…”
Get full text

Detection of circulating tumor cells in colorectal cancer by immunobead-PCR is a sensitive prognostic marker for relapse of disease by Hardingham, J E, Kotasek, D, Sage, R E, Eaton, M C, Pascoe, V H, Dobrovic, A

“…Recurrent and metastatic carcinoma of the colorectum remains a major problem, with survival at 5 years post curative resection still only about 50%. Moreover,…”
Get full text

Immunobead-PCR : a technique for the detection of circulating tumor cells using immunomagnetic beads and the polymerase chain reaction by HARDINGHAM, J. E, KOTASEK, D, FARMER, B, BUTLER, R. N, JING-XIAN MI, SAGE, R. E, DOBROVIC, A

“…The presence of tumor cells in the circulation may predict disease recurrence and metastases. We have developed a sensitive technique for the detection of…”
Get full text

Immunobead RT-PCR: a sensitive method for detection of circulating tumor cells by Eaton, M C, Hardingham, J E, Kotasek, D, Dobrovic, A

“…Detection of circulating tumor cells and micrometastases in patients with cancer should prove useful in determining prognosis and in planning and monitoring…”
Get full text

Dipeptidase 1: a candidate tumor-specific molecular marker in colorectal carcinoma by McIver, C.M, Lloyd, J.M, Hewett, P.J, Hardingham, J.E

“…The aim of this study was to identify tumor-specific markers for the detection of rare disseminated colorectal tumor cells in peripheral venous blood and in…”
Get full text

Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma by Hardingham, J E, Kotasek, D, Sage, R E, Gooley, L T, Mi, J X, Dobrovic, A, Norman, J E, Bolton, A E, Dale, B M

“…To evaluate the significance of molecular marker-positive cells in a cohort of non-Hodgkin's lymphoma (NHL) patients undergoing high-dose chemotherapy and…”
Get more information

Molecular detection of residual lymphoma cells in peripheral blood stem cell harvests and following autologous transplantation by Hardingham, J E, Kotasek, D, Sage, R E, Dobrovic, A, Gooley, T, Dale, B M

“…Twenty-seven patients with non-Hodgkin's lymphoma (NHL) have undergone peripheral blood stem cell (PBSC) harvesting for autologous transplantation (Tx). A…”
Get more information

Bevacizumab first line and impact on subsequent anti-EGFR activity by Price, T.J., Hardingham, J., Karapetis, C., Smith, E., Padbury, R., Roy, A., Roder, D., Burge, M.E., Townsend, A.

Get full text

Molecular Subgroups from the Agitg Max Trial; Right or Left Primary Site of Colorectal Cancer and Outcomes for Metastatic Colorectal Cancer (Mcrc) by Price, T.J., Buizen, L., Hardingham, J., Lee, C.K., Townsend, A., Bruhn, M., Simes, R.J., Wilson, K., Gebski, V., Tebbutt, N.C.

Get full text

511PMOLECULAR SUBGROUPS FROM THE AGITG MAX TRIAL; RIGHT OR LEFT PRIMARY SITE OF COLORECTAL CANCER AND OUTCOMES FOR METASTATIC COLORECTAL CANCER (MCRC) by Price, T.J., Buizen, L., Hardingham, J., Lee, C.K., Townsend, A., Bruhn, M., Simes, R.J., Wilson, K., Gebski, V., Tebbutt, N.C.

“…Abstract Aim: Previous reports have described differences in biology and outcome based on whether the primary is right (R) or left (L) sided. Possible…”
Get full text

Are Patients with Resectable Rectal Cancer Better Off in the Era of Multidisciplinary Care? by Broadbridge, V.T., Hardingham, J., Pittman, K., Townsend, A., Colbeck, M., Hooper, B., Price, T.

Get full text

612P - Are Patients with Resectable Rectal Cancer Better Off in the Era of Multidisciplinary Care? by Broadbridge, V.T., Hardingham, J., Pittman, K., Townsend, A., Colbeck, M., Hooper, B., Price, T.

“…The management of rectal cancer (RC) has evolved with the introduction of Total Mesorectal Excision Surgery (TME), use of Magnetic Resonance Imaging (MRI) for…”
Get full text

Pten and Advanced Colorectal Cancer (CRC): Analysis from the Phase III Agitg Max Trial of Capecitabine Alone or in Combination with Bevacizumab +/- Mitomycin C by Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Wilson, K., Weickhardt, A., Simes, R.J., Munroe, C., Tebbutt, N.

Get full text

532P - Pten and Advanced Colorectal Cancer (CRC): Analysis from the Phase III Agitg Max Trial of Capecitabine Alone or in Combination with Bevacizumab +/- Mitomycin C by Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Wilson, K., Weickhardt, A., Simes, R.J., Munroe, C., Tebbutt, N.

“…The tumour suppressor gene PTEN may have a role as a biomarker for anti-EGFR therapy in CRC. As PTEN expression also has a relationship with VEGF expression…”
Get full text

A phase Ib/II study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer with KRAS wild type (WT) by Townsend, A. R., Pirc, L., Hardingham, J., Karapetis, C. S., Tebbutt, N. C., Singhal, N., Price, T. J.

“…Abstract only…”
Get full text